Supplementary material

Bacharach J, Tatham A, Ferguson G, Belalcázar S, Thieme H, Goodkin ML, Chen MY, Guo Q, Liu J, Robinson MR, Bejanian M, Wirta DL; on behalf of the ARTEMIS 2 Study Group. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). *Drugs*.

Author for correspondence: Jason Bacharach, MD; North Bay Eye Associates, Petaluma, CA, USA; Email: jbacharach@northbayeye.com

Online Resource 2



Schematic of study design showing timing of study treatments and assessments. Bimatoprost implant or sham procedure was administered in study eyes on Day 1, Week 16, and Week 32 (administration visits). In addition to the study visits shown, safety visits were scheduled 1 day after the administration visits, and 6 phone calls were made for safety assessment at 3 and 7 days after each administration visit. *BID* twice daily, *BL* Baseline, *Scr* Screening, *timolol* timolol maleate 0.5% ophthalmic solution